J&J explores $20B+ sale of DePuy Synthes orthopedics unit to PE and strategic buyers, pivoting from October spinoff plan. Would reshape global ortho market.

J&J Explores $20 Billion Sale of DePuy Synthes, Pivoting From Spinoff Plan

J&J invests $1B+ in Pennsylvania cell therapy plant, creating 4,500 jobs. Part of $55B US manufacturing push as Carvykti sales doubled to $1.9B.

Johnson & Johnson Bets $1 Billion on Pennsylvania Cell Therapy Plant as Carvykti Sales Near $2 Billion

J&J beats Q4 estimates, raises 2026 guidance to $100B+ sales. But federal judge allows expert testimony linking talc to cancer in 67,500+ lawsuits.

J&J's $527B Question: Strong Earnings Collide with Major Talc Litigation Ruling

J&J Hit With Record $1.56 Billion Talc Verdict as Bankruptcy Strategy Unravels

Q4 2025

Q3 2025

Q2 2025

Q1 2025

Q4 2024

Q3 2024

Q2 2024

Q1 2024

Q4 2023

Q3 2023

Q2 2023

Q1 2023

JOHNSON & JOHNSON (JNJ) Earnings Call Transcripts